<?xml version="1.0" encoding="UTF-8"?>
<p>Pancreatic cancer is the seventh leading cause of global cancer deaths in industrialized countries (
 <xref rid="B1" ref-type="bibr">1</xref>). The majority of patients present with locally advanced or metastatic disease at initial diagnosis (
 <xref rid="B2" ref-type="bibr">2</xref>, 
 <xref rid="B3" ref-type="bibr">3</xref>), which leads to poor prognosis and a 5-year survival at 7% (
 <xref rid="B4" ref-type="bibr">4</xref>). Although the clinical outcome is still limited, chemotherapy remains the primary treatment modality for patients with metastatic pancreatic cancer (
 <xref rid="B5" ref-type="bibr">5</xref>). Given liver metastasis is most frequent situation and primarily responsible for the high mortality of pancreatic cancer (
 <xref rid="B6" ref-type="bibr">6</xref>), robust management of intrahepatic lesions may provide survival benefit.
</p>
